Genetic conversion of an SMN2 gene to SMN1: A novel approach to the treatment of spinal muscular atrophy

Experimental Cell Research

Volumn 314, Issue 4, 2008, Pages 878-886

  DiMatteo, Darlise ^a   Callahan, Stephanie ^a   Kmiec, Eric B ^a  

^a UNIVERSITY OF DELAWARE   (United States)

Author keywords

Gene alteration; Single stranded oligonucleotides; SMA

Indexed keywords

PROTEIN SMN1; PROTEIN SMN2; SURVIVAL MOTOR NEURON PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; DNA STRAND; GENE LOCUS; GENE SEQUENCE; GENOTYPE; HUMAN; HUMAN CELL; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; RESTRICTION MAPPING; SKIN FIBROBLAST; SPINAL MUSCULAR ATROPHY;

EID: 38949190657     PISSN: 00144827     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.yexcr.2007.10.012     Document Type: Article

References (34)

1. Lefebvre S., Burglen L., Reboullet S., Clermont O., Burlet P., Viollet L., Benichou B., Cruaud C., Millasseau P., and Zeviani M. Identification and characterization of a spinal muscular atrophy-determining gene. Cell 80 (1995) 155-165
2. Lorson C.L., Hahnen E., Androphy E.J., and Wirth B. A single nucleotide in the SMN gene regulates splicing and is responsible for spinal muscular atrophy. Proc. Natl. Acad. Sci. U. S. A. 96 (1999) 6307-6311
3. Kashima T., and Manley J.L. A negative element in SMN2 exon 7 inhibits splicing in spinal muscular atrophy. Nat. Genet. 34 (2003) 460-463
4. Monani U.R., Coovert D.D., and Burghes A.H. Animal models of spinal muscular atrophy. Hum. Mol. Genet. 9 (2000) 2451-2457
5. Cartegni L., and Krainer A.R. Disruption of an SF2/ASF-dependent exonic splicing enhancer in SMN2 causes spinal muscular atrophy in the absence of SMN1. Nat. Genet. 30 (2002) 377-384
6. Lorson C.L., and Androphy E.J. An exonic enhancer is required for inclusion of an essential exon in the SMA-determining gene SMN. Hum. Mol. Genet. 9 (2000) 259-265
7. Feldkotter M., Schwarzer V., Wirth R., Wienker T.F., and Wirth B. Quantitative analyses of SMN1 and SMN2 based on real-time lightCycler PCR: fast and highly reliable carrier testing and prediction of severity of spinal muscular atrophy. Am. J. Hum. Genet. 70 (2002) 358-368
8. Brahe C., Vitali T., Tiziano F.D., Angelozzi C., Pinto A.M., Borgo F., Moscato U., Bertini E., Mercuri E., and Neri G. Phenylbutyrate increases SMN gene expression in spinal muscular atrophy patients. Eur. J. Hum. Genet. 13 (2005) 256-259
9. Brichta L., Holker I., Haug K., Klockgether T., and Wirth B. In vivo activation of SMN in spinal muscular atrophy carriers and patients treated with valproate. Ann. Neurol. 59 (2006) 970-975
10. DiDonato C.J., Parks R.J., and Kothary R. Development of a gene therapy strategy for the restoration of survival motor neuron protein expression: implications for spinal muscular atrophy therapy. Hum. Gene Ther. 14 (2003) 179-188
11. Azzouz M., Le T., Ralph G.S., Walmsley L., Monani U.R., Lee D.C., Wilkes F., Mitrophanous K.A., Kingsman S.M., Burghes A.H., and Mazarakis N.D. Lentivector-mediated SMN replacement in a mouse model of spinal muscular atrophy. J. Clin. Invest. 114 (2004) 1726-1731
12. Parekh-Olmedo H., Ferrara L., Brachman E., and Kmiec E.B. Gene therapy progress and prospects: targeted gene repair. Gene Ther. 12 (2005) 639-646
13. Sangiuolo F., Filareto A., Spitalieri P., Scaldaferri M.L., Mango R., Bruscia E., Citro G., Brunetti E., De Felici M., and Novelli G. In vitro restoration of functional SMN protein in human trophoblast cells affected by spinal muscular atrophy by small fragment homologous replacement. Hum. Gene Ther. 16 (2005) 869-880
14. Baughan T., Shababi M., Coady T.H., Dickson A.M., Tullis G.E., and Lorson C.L. Stimulating full-length SMN2 expression by delivering bifunctional RNAs via a viral vector. Mol. Ther. 14 (2006) 54-62
15. Hua Y., Vickers T.A., Baker B.F., Bennett C.F., and Krainer A.R. Enhancement of SMN2 exon 7 inclusion by antisense oligonucleotides targeting the exon. PLoS Biol. 5 (2007) e73
16. Anhuf D., Eggermann T., Rudnik-Schoneborn S., and Zerres K. Determination of SMN1 and SMN2 copy number using TaqMan technology. Human Mutat. 22 (2003) 74-78
17. Grzeschik S.M., Ganta M., Prior T.W., Heavlin W.D., and Wang C.H. Hydroxyurea enhances SMN2 gene expression in spinal muscular atrophy cells. Ann. Neurol. 58 (2005) 194-202
18. Burlet P., Frydman N., Gigarel N., Bonnefont J.P., Kerbrat V., Tachdjian G., Frydman R., Munnich A., Steffann J., and Ray P.F. Improved single-cell protocol for preimplantation genetic diagnosis of spinal muscular atrophy. Fertil. Steril. 84 (2005) 734-739
19. Andreassi C., Angelozzi C., Tiziano F.D., Vitali T., De Vincenzi E., Boninsegna A., Villanova M., Bertini E., Pini A., Neri G., and Brahe C. Phenylbutyrate increases SMN expression in vitro: relevance for treatment of spinal muscular atrophy. Eur. J. Hum. Genet. 12 (2004) 59-65
20. Liu L., Rice M.C., and Kmiec E.B. In vivo gene repair of point and frameshift mutations directed by chimeric RNA/DNA oligonucleotides and modified single-stranded oligonucleotides. Nucleic Acids Res. 29 (2001) 4238-4250
21. Liu L., Rice M.C., Drury M., Cheng S., Gamper H., and Kmiec E.B. Strand bias in targeted gene repair is influenced by transcriptional activity. Mol. Cell. Biol. 22 (2002) 3852-3863
22. Brachman E.E., and Kmiec E.B. DNA replication and transcription direct a DNA strand bias in the process of targeted gene repair in mammalian cells. J. Cell Sci. 117 (2004) 3867-3874
23. Coovert D.D., Le T.T., McAndrew P.E., Strasswimmer J., Crawford T.O., Mendell J.R., Coulson S.E., Androphy E.J., Prior T.W., and Burghes A.H. The survival motor neuron protein in spinal muscular atrophy. Hum. Mol. Genet. 6 (1997) 1205-1214
24. Hu Y., Parekh-Olmedo H., Drury M., Skogen M., and Kmiec E.B. Reaction parameters of targeted gene repair in Mammalian cells. Mol. Biotechnol. 29 (2005) 197-210
25. Drury M.D., Skogen M.J., and Kmiec E.B. A tolerance of DNA heterology in the mammalian targeted gene repair reaction. Oligonucleotides 15 (2005) 155-171
26. Bertoni C., Morris G.E., and Rando T.A. Strand bias in oligonucleotide-mediated dystrophin gene editing. Hum. Mol. Genet. 14 (2005) 221-233
27. Jarecki J., Chen X., Bernardino A., Coovert D.D., Whitney M., Burghes A., Stack J., and Pollok B.A. Diverse small-molecule modulators of SMN expression found by high-throughput compound screening: early leads towards a therapeutic for spinal muscular atrophy. Hum. Mol. Genet. 14 (2005) 2003-2018
28. Sumner C.J., Huynh T.N., Markowitz J.A., Perhac J.S., Hill B., Coovert D.D., Schussler K., Chen X., Jarecki J., Burghes A.H., Taylor J.P., and Fischbeck K.H. Valproic acid increases SMN levels in spinal muscular atrophy patient cells. Ann. Neurol. 54 (2003) 647-654
29. Mattis V.B., Rai R., Wang J., Chang C.W., Coady T., and Lorson C.L. Novel aminoglycosides increase SMN levels in spinal muscular atrophy fibroblasts. Hum. Genet. 120 (2006) 589-601
30. Avila A.M., Burnett B.G., Taye A.A., Gabanella F., Knight M.A., Hartenstein P., Cizman Z., Di Prospero N.A., Pellizzoni L., Fischbeck K.H., and Sumner C.J. Trichostatin A increases SMN expression and survival in a mouse model of spinal muscular atrophy. J. Clin. Invest. 117 (2007) 659-671
31. Chang J.G., Hsieh-Li H.M., Jong Y.J., Wang N.M., Tsai C.H., and Li H. Treatment of spinal muscular atrophy by sodium butyrate. Proc. Natl. Acad. Sci. U. S. A. 98 (2001) 9808-9813
32. Tsai L.K., Tsai M.S., Lin T.B., Hwu W.L., and Li H. Establishing a standardized therapeutic testing protocol for spinal muscular atrophy. Neurobiol. Dis. 24 (2006) 286-295
33. Bartlett R.J., Stockinger S., Denis M.M., Bartlett W.T., Inverardi L., Le T.T., thi M.N., Morris G.E., Bogan D.J., Metcalf-Bogan J., and Kornegay J.N. In vivo targeted repair of a point mutation in the canine dystrophin gene by a chimeric RNA/DNA oligonucleotide. Nat. Biotechnol. 18 (2000) 615-622
34. Federici T., and Boulis N.M. Gene-based treatment of motor neuron diseases. Muscle Nerve 33 (2006) 302-323